You are here

Home

SUVALENT THERAPEUTICS INC.

Company Information
Address
1290 Rancho Conejo Blvd, Ste 101F
Thousand Oaks, CA 91320-1408
United States
Information

UEI: V5T3JYKJJ7D1

# of Employees: 7
Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No

Award Charts




Award Listing

  • Record 1 TO 4

  1. Orally available allosteric inhibitor of protein sumoylation

    Amount: $300,000.00

    PROJECT SUMMARY ABSTRACT Extensive studies have indicated that post translational modification by the small ubiquitin like modifierSUMOfamily of proteins is a promising cancer therapeutic targetc Myc ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health

  2. Development of an oral drug targeting SUMOylation

    Amount: $232,759.00

    c Mycand KRas dependent cancerssuch as colorectal cancerrepresent major unmet medical needs that currently lack targeted therapyRecent scientific advances revealed that theseundruggableoncogenes criti ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health

  3. Design of a Covalent Inhibitor for c-Myc-Dependent Cancers

    Amount: $1,997,648.00

    DESCRIPTION provided by applicant The main commercial goal of our company is to develop novel therapeutics to inhibit the human oncogene c Myc C Myc is a major human oncogene that is estimated to ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health

  4. Design of a Covalent Inhibitor for c-Myc-Dependent Cancers

    Amount: $224,999.00

    DESCRIPTION (provided by applicant): The leading commercial goal of our company is to develop novel therapeutics to inhibit the human oncogene, c-Myc. C-Myc is a major human oncogene that is estimated ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government